



Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

24th March, 2026

To
The Secretary,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

To
The Manager,
Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, C-1,
G Block, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051

Scrip Code: 524816

Scrip Symbol: NATCOPHARM

Dear Sir/ Madam,

Undertaking for submission of No Objection Certificate (NOC)

Sub: Application under Regulation 37(1) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (“SEBI (LODR) Regulations, 2015”) for the proposed Scheme of Arrangement between Natco Pharma Limited (“NPL” or “the Demerged Company”) and Natco Crop Health Sciences Limited (“NCHSL” or “the Resulting Company”) and their respective Shareholders and Creditors

We hereby confirm that we have initiated the process of obtaining the No Objection Certificate from the lending scheduled commercial banks/financial institutions/debenture trustees (as applicable) as required under Para A(2)(k) of Part I of SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023, and we shall submit the same with the Exchange before the receipt of the No-objection letter from stock exchange in terms of Regulation 37(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Note: In case any conditionality is placed in the NOC given by the lenders, the Company shall provide the impact of such conditionality on the Scheme, if any.

Thanking you,

Yours faithfully,
For Natco Pharma Limited

Chekuri Venkat Ramesh
Company Secretary &
Compliance Officer